SomnoMed Limited
SomnoMed Limited Fundamental Analysis
SomnoMed Limited (SOM.AX) shows moderate financial fundamentals with a PE ratio of -52.54, profit margin of -2.16%, and ROE of -5.31%. The company generates $0.1B in annual revenue with strong year-over-year growth of 21.65%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 39.1/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze SOM.AX's fundamental strength across five key dimensions:
Efficiency Score
WeakSOM.AX struggles to generate sufficient returns from assets.
Valuation Score
ExcellentSOM.AX trades at attractive valuation levels.
Growth Score
ExcellentSOM.AX delivers strong and consistent growth momentum.
Financial Health Score
ExcellentSOM.AX maintains a strong and stable balance sheet.
Profitability Score
WeakSOM.AX struggles to sustain strong margins.
Key Financial Metrics
Is SOM.AX Expensive or Cheap?
P/E Ratio
SOM.AX trades at -52.54 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, SOM.AX's PEG of -1.94 indicates potential undervaluation.
Price to Book
The market values SomnoMed Limited at 2.69 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 33.49 times EBITDA. This signals the market has high growth expectations.
How Well Does SOM.AX Make Money?
Net Profit Margin
For every $100 in sales, SomnoMed Limited keeps $-2.16 as profit after all expenses.
Operating Margin
Core operations generate 2.35 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $-5.31 in profit for every $100 of shareholder equity.
ROA
SomnoMed Limited generates $-3.20 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
SomnoMed Limited generates limited operating cash flow of $7.94M, signaling weaker underlying cash strength.
Free Cash Flow
SomnoMed Limited produces free cash flow of $3.74M, offering steady but limited capital for shareholder returns and expansion.
FCF Per Share
Each share generates $0.02 in free cash annually.
FCF Yield
SOM.AX converts 2.73% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
-52.54
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-1.94
vs 25 benchmark
P/B Ratio
Price to book value ratio
2.69
vs 25 benchmark
P/S Ratio
Price to sales ratio
1.15
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.28
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.76
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
-0.05
vs 25 benchmark
ROA
Return on assets percentage
-0.03
vs 25 benchmark
ROCE
Return on capital employed
0.05
vs 25 benchmark
How SOM.AX Stacks Against Its Sector Peers
| Metric | SOM.AX Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | -52.54 | 28.31 | Better (Cheaper) |
| ROE | -5.31% | 699.00% | Weak |
| Net Margin | -2.16% | -130884.00% (disorted) | Weak |
| Debt/Equity | 0.28 | 0.34 | Neutral |
| Current Ratio | 1.76 | 2775.16 | Neutral |
| ROA | -3.20% | -14469.00% (disorted) | Weak |
SOM.AX outperforms its industry in 1 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews SomnoMed Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
-39.38%
Industry Style: Defensive, Growth, Innovation
DecliningEPS CAGR
3.73%
Industry Style: Defensive, Growth, Innovation
GrowingFCF CAGR
-53.27%
Industry Style: Defensive, Growth, Innovation
Declining